These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 15235076)

  • 21. Impact of interpatient pharmacokinetic variability on design considerations for therapy with radiolabeled MAbs.
    DeNardo G; Yuan A; Goldstein D; Richman C; O'Donnell R; Shen S; Hartmann Siantar C; DeNardo S
    Cancer Biother Radiopharm; 2003 Apr; 18(2):231-7. PubMed ID: 12804049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cure of incurable lymphoma.
    DeNardo GL; Sysko VV; DeNardo SJ
    Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S46-56. PubMed ID: 16979440
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study.
    Cooney-Qualter E; Krailo M; Angiolillo A; Fawwaz RA; Wiseman G; Harrison L; Kohl V; Adamson PC; Ayello J; vande Ven C; Perkins SL; Cairo MS;
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5652s-5660s. PubMed ID: 17875803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of anthropomorphic hand phantoms for personal dosimetry in 90Y-Zevalin preparation and patient delivering.
    Ciolini R; d'Errico F; Traino AC; Paternostro E; Laganà A; Romei C; Pazzagli F; Del Gratta A
    Radiat Prot Dosimetry; 2014 Jan; 158(2):216-20. PubMed ID: 23960242
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rituximab maintenance versus radio-immunotherapy consolidation in first remission follicular non-Hodgkin lymphoma.
    Hagenbeek A
    Transfus Apher Sci; 2013 Aug; 49(1):43. PubMed ID: 23932512
    [No Abstract]   [Full Text] [Related]  

  • 26. Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis.
    Song H; Du Y; Sgouros G; Prideaux A; Frey E; Wahl RL
    J Nucl Med; 2007 Jan; 48(1):150-7. PubMed ID: 17204712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. B-cell non-Hodgkin lymphoma: PET/CT evaluation after 90Y-ibritumomab tiuxetan radioimmunotherapy--initial experience.
    Ulaner GA; Colletti PM; Conti PS
    Radiology; 2008 Mar; 246(3):895-902. PubMed ID: 18258810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
    Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
    J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response.
    Sgouros G; Squeri S; Ballangrud AM; Kolbert KS; Teitcher JB; Panageas KS; Finn RD; Divgi CR; Larson SM; Zelenetz AD
    J Nucl Med; 2003 Feb; 44(2):260-8. PubMed ID: 12571219
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radioimmunotherapy of non-Hodgkin's lymphoma: molecular targeting and novel agents.
    Pauwels EK; Erba P
    Drug News Perspect; 2007 Mar; 20(2):87-93. PubMed ID: 17440631
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results.
    Weiden PL; Breitz HB; Press O; Appelbaum JW; Bryan JK; Gaffigan S; Stone D; Axworthy D; Fisher D; Reno J
    Cancer Biother Radiopharm; 2000 Feb; 15(1):15-29. PubMed ID: 10740649
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
    Konijnenberg MW; Bijster M; Krenning EP; De Jong M
    J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor-Absorbed Dose Predicts Progression-Free Survival Following (131)I-Tositumomab Radioimmunotherapy.
    Dewaraja YK; Schipper MJ; Shen J; Smith LB; Murgic J; Savas H; Youssef E; Regan D; Wilderman SJ; Roberson PL; Kaminski MS; Avram AM
    J Nucl Med; 2014 Jul; 55(7):1047-53. PubMed ID: 24842891
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Personalized dosimetry of 131I-rituximab radioimmunotherapy of non-hodgkin lymphoma defined by pharmacokinetics in bone marrow and blood.
    Boucek JA; Turner JH
    Cancer Biother Radiopharm; 2014 Feb; 29(1):18-25. PubMed ID: 24134141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison between 2D and 3D dosimetry protocols in 90Y-ibritumomab tiuxetan radioimmunotherapy of patients with non-Hodgkin's lymphoma.
    Assié K; Dieudonné A; Gardin I; Buvat I; Tilly H; Vera P
    Cancer Biother Radiopharm; 2008 Feb; 23(1):53-64. PubMed ID: 18298329
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ongoing investigations and new uses of radioimmunotherapy in the treatment of non-Hodgkin's lymphoma.
    Meredith RF
    Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S23-9. PubMed ID: 16979435
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Radioimmunotherapy in non-Hodgkin's lymphoma. With focus on anti-CD20 treatment].
    de Nully Brown P; Jurlander J; Lindén O; Hansen M
    Ugeskr Laeger; 2005 Oct; 167(41):3867-9. PubMed ID: 16221425
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Change in tumor-absorbed dose due to decrease in mass during fractionated radioimmunotherapy in lymphoma patients.
    Hindorf C; Lindén O; Stenberg L; Tennvall J; Strand SE
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):4003S-6S. PubMed ID: 14506200
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study.
    Denardo GL; Denardo SJ; Kukis DL; O'Donnell RT; Shen S; Goldstein DS; Kroger LA; Salako Q; Denardo DA; Mirick GR; Mausner LF; Srivastava SC; Meares CF
    Anticancer Res; 1998; 18(4B):2779-88. PubMed ID: 9713461
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New directions in the therapeutic strategy to improve survival outcomes in patients with non-Hodgkin's lymphoma. Summary.
    Bischof Delaloye A; Conti PS; Gisselbrecht C; Gregory SA
    Oncologist; 2009; 14 Suppl 2():52-4. PubMed ID: 19819924
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.